Search
Afasevikumab
go.drugbank.com/drugs/DB14798InvestigationalAfasevikumab is under investigation in clinical trial NCT01480310 (Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers).
Obefazimod
go.drugbank.com/drugs/DB14828InvestigationalABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Flutriciclamide F-18
go.drugbank.com/drugs/DB15380ExperimentalFlutriciclamide F-18 is under investigation in clinical trial NCT02350426 (A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques).
AZD8529
go.drugbank.com/drugs/DB16073InvestigationalAZD8529 is under investigation in clinical trial NCT00921804 (Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients).
Eftilagimod alfa
go.drugbank.com/drugs/DB16150InvestigationalEftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).
Landipirdine
go.drugbank.com/drugs/DB16214InvestigationalLandipirdine is under investigation in clinical trial NCT02258152 (SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)).
Octovalent O-polysaccharide-toxin A conjugate vaccine
go.drugbank.com/drugs/DB17789ExperimentalOctovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.[A259462]
Synonyms: Octovalent O-polysaccharide-toxin A conjugate vaccine, octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugateDCN-tCRK
go.drugbank.com/drugs/DB18262ExperimentalDCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
MB-107
go.drugbank.com/drugs/DB18566ExperimentalMB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.